BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FivePrime Therapeutics, Inc. CEO Done After Two Years, Rusty Williams Takes Over


8/18/2011 6:56:25 AM

San Francisco Business Times - by Ron Leuty

Five Prime Therapeutics Five Prime Therapeutics Latest from The Business Journals QB3 spotlights University of California science, 'American Idol'-style150 Most Influential Women in Bay Area business namedFivePrime, Dyax enter antibody R&D deal Follow this company founder Lewis “Rusty” Williams has replaced Julia Gregory as CEO, Elsevier Inc.’s In Vivo Blog reported.

A Five Prime spokeswoman confirmed that Gregory is no longer with the company, the blog reported. A Five Prime spokeswoman did not return a phone message left by the San Francisco Business Times.

Gregory replaced Gail Maderis as CEO in 2009, coming from Lexicon Pharmaceuticals. During her tenure, the antibody drug development company signed a potential $500 million licensing deal with Human Genome Sciences that included a $50 million upfront payment.

Gregory also moved the privately held company from San Francisco’s Mission Bay biotech enclave to South San Francisco and was largely expected to help the company raise its profile with investment bankers. At Lexicon, she led finance and business development.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES